Breaking News Instant updates and real-time market news.

MDRX

Allscripts

$15.11

0.13 (0.87%)

05:20
01/04/18
01/04
05:20
01/04/18
05:20

Allscripts initiated with a Buy at Citi

Citi analyst Stephanie Davis started Allscripts with a Buy rating and $18 price target. A valuation at the low end of peer group is unjustified, the analyst contends.

MDRX Allscripts
$15.11

0.13 (0.87%)

09/11/17
COWN
09/11/17
UPGRADE
Target $159
COWN
Outperform
Allscripts upgraded to Outperform from Market Perform at Cowen
Cowen analyst Charles Rihyee upgraded Allscripts to Outperform and increased its price target to $16 from $13 citing improving fundamentals and the EIS acquisition. The analyst said there are a number of drivers not reflected in valuation including mix shifts in the core business towards higher growth areas, incremental earnings and margin expansion from the EIS acquisition, strong free cash flow and capital deployment, and updated guidance that could prove to be conservative.
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Outperform
Allscripts initiated with an Outperform at RBC Capital
RBC Capital analyst George Hill started coverage of Allscripts with a $17 price target and an Outperform rating. He is upbeat on Allscripts as he says that the shares are attractive due to the company's "core business execution, positioning for next generation HCIT solutions, accretion from the EIS acquisition, and valuation." He calls the company "an industry leader in Population Health Management and in revenue cycle management."
11/24/17
LEER
11/24/17
NO CHANGE
LEER
Market Perform
Cerner could get more competitive with Allscripts via Amazon pact, says Leerink
Leerink analyst David Larsen said he thinks Cerner (CERN) and Amazon (AMZN) may already have an existing relationship and the announcement teased in the report by CNBC may be to state that HealtheIntent will rely more heavily on Amazon Web Services. Improvements in Cerner's population health management platform could make it more competitive against Allscripts (MDRX), Quality Systems (QSII) and possibly athenahealth (ATHN), added Larsen, who keeps a Market Perform rating on Cerner shares.
11/24/17
MSCO
11/24/17
NO CHANGE
MSCO
Morgan Stanley says Cerner could be Amazon's 'Trojan horse' into hospitals
Following a report that Cerner (CERN) and Amazon's (AMZN) AWS are in the final stages of partnership negotiations that would see Amazon provide cloud services for Cerner's population health product, HealtheIntent, Morgan Stanley analyst Ricky Goldwasser said a Cerner partnership could be the "Trojan horse" that helps Amazon build hospital relationships to compete against established GPOs and medical distributors. From Cerner's side, the partnership gives them a leg up in population health relative to competitors like Allscripts (MDRX) and athenahealth (ATHN), said Goldwasser, who wonders if this announcement will lead to other cloud /healthcare IT partnerships with the likes of Microsoft (MSFT) and Google (GOOGL).

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.